AlamarBio

Join us live from Amsterdam UMC on May 21 as researchers discuss ultra-sensitive proteomics and biomarker discovery in dementia & MS - with live online access available. Featuring speakers from AUMC, DZNE, UCL, HKUST & Barcelonaβeta/Lund. 👉 Register: na2.hubs.ly/H05kGNX0

📍 We’ll be at XXXIV AINI Congress in Rome! Learn how ultra-sensitive, multiplex proteomics can reveal biomarkers that refine MS phenotyping and biology in our speaker session with Anna Wojdala, PhD (Amsterdam UMC). 👉 na2.hubs.ly/H05cfJj0

🧬 International Day of Immunology Our ultra-sensitive NULISA technologies help researchers measure low-abundance biomarkers and uncover the biology driving disease. We're proud to support the research advancing the boundaries of immunology. #InternationalDayofImmunology

“Under-promise and over deliver. And that has been the philosophy of building this company." @AlamarBio Founder, Chairman, and CEO Yuling Luo shares the $ALMR journey to listing day. #NasdaqListed

Happening this week, CSI brings together researchers advancing immunology. See how NULISA™ enables ultra-sensitive, multiplex protein analysis for low-abundance biomarkers and deeper insights. Visit our table to learn more.

Join our webinar with Labroots featuring Dr. Steve Williams, CSO at Alamar Biosciences, to learn how NULISA™ enables ultra-sensitive, multiplex detection of low-abundance protein biomarkers from small blood samples. Register now: na2.hubs.ly/H053N8F0

The past week marked an important milestone for Alamar. Our focus remains the same: powering precision proteomics to enable earlier disease detection. We’re grateful to our community and energized for what’s ahead. #NasdaqListed $ALMR

A milestone moment for Alamar. Grateful to our team, customers, partners, and investors who made this possible. Listing on @Nasdaq marks a new chapter as we continue advancing ultra‑sensitive, multiplex precision proteomics for earlier disease detection.🚀 #NasdaqListed $ALMR

🚨 Only two weeks left to apply for the Parkinson’s Disease Grant Program. Apply by April 30, 2026, for a chance to receive one of 3 awards, including analysis of 86 samples using the NULISAseq™ Neuro 220 Panel. 🔗 Apply now: na2.hubs.ly/H04Vxq_0

Join our Spotlight Theater at AACR featuring Adam Grippin, Aaron Kilgallon, and Steve Williams on how NULISA is being applied to uncover low-abundance biomarkers, profile complex tumor and immune biology, and accelerate translational research. 👉 na2.hubs.ly/H04TTGY0

We’re onsite in Boston for the 8th Annual NDDS, bringing together leaders across biotech, pharma, and academia to advance neuroimmune therapies. Join Max Mahoney (Alamar Biosciences) for tomorrow's presentation on the NULISA Platform. 👉 na2.hubs.ly/H04SBVx0

Parkinson’s disease affects more than 10 million people globally and often begins long before symptoms appear, making early understanding critical. We’re committed to earlier detection through ultra-sensitive precision proteomics to help uncover the signals that matter.

@erzimmer @zimmerneurolab Great to see NULISA expanding into Brazil! We're excited to support the important work coming out of @zimmerneurolab

@AlamarBio is now in the south of 🇧🇷! A lot of diversity on AD biomarkers coming soon! 🩸 @zimmerneurolab

We’re heading to WRIB 2026 next week in Dallas, TX. Stop by booth 86 to learn how the #NULISA Platform supports inflammation biomarker analysis from discovery through clinical development. Learn more: na2.hubs.ly/H04PSjg0

The cancer research community comes together at AACR! Join us at #AACR26 in San Diego, where the latest advances across cancer biology, translational science, and clinical research come together. Stop by booth 3953 to connect with us. Learn more: na2.hubs.ly/H04KXhR0

Working on a Parkinson’s disease research project? Apply by April 30, 2026 for Alamar’s Parkinson’s Disease Grant Program—3 awards available, including analysis of 86 samples using the new NULISAseq™ Neuro 220 Panel. 👉 Apply now: na2.hubs.ly/H04FqBL0

Join co-chairs Robert Rissman and Nicholas Ashton at the Synuclein Biomarker & Neuropathology Summit 2026, bringing together experts to advance synuclein research, biomarker discovery, and therapeutic strategies. 🔗 Register today to secure your spot: na2.hubs.ly/H04CQzb0

Welcome Allumiqs, our newest CSP for the ARGO™ HT platform powered by NULISA™. A CRO delivering omics‑driven insights, Allumiqs now brings NULISA precision proteomics to accelerate translational research and biomarker discovery. About Allumiqs: na2.hubs.ly/H04zxqG0

🧠 Live from the 16th Annual Traumatic Brain Injury Conference in Philadelphia. We’re here with researchers, clinicians, and industry leaders advancing TBI research. Don’t miss how NULISA™ enables ultra-sensitive, high-multiplex protein profiling. 👉 na2.hubs.ly/H04y_cD0

Happening tomorrow 🚨 St. Louis Precision Proteomics Summit Join us at Washington University in St. Louis for new insights advancing Alzheimer’s & brain disease research through ultra-sensitive, high-multiplex proteomics. 👉 Save your seat: na2.hubs.ly/H04qRvz0